FRI0368 The use of ultrasound in the diagnosis and management of patients with giant cell arteritis: experience of a single centre

FRI0368 The use of ultrasound in the diagnosis and management of patients with giant cell arteritis: experience of a single centre

Opis bibliograficzny
Główni autorzy:	Ponte, C, Floris, A, Vaggers, S, Goodfellow, N, Sznajd, J, O'Neill, L, Piper, J, Gunn, J, Mankia, K, Luqmani, R
Format:	Conference item
Wydane:	BMJ Publishing Group 2016

Podobne zapisy

The role of ultrasound in the management of giant cell arteritis in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

The proposed role of ultrasound in the management of giant cell arteritis in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

THU0296 The role of ultrasound in the management of giant cell arteritis (GCA) in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

The role of a standardised ultrasound protocol in the management of giant cell arteritis (GCA) in routine clinical practice
od: Monti, S, i wsp.
Wydane: (2017)

FRI0028 Vascular Endothelial Growth Factor as An Aid To Diagnosis of Giant Cell Arteritis
od: Goodfellow, N, i wsp.
Wydane: (2016)

The use of ultrasound to assess giant cell arteritis: Review of the current evidence and practical guide for the rheumatologist
od: Monti, S, i wsp.
Wydane: (2017)

Giant cell arteritis: Current treatment and management
od: Ponte, C, i wsp.
Wydane: (2015)

FRI0312 The frequency and severity of patient-reported symptoms in giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

THU0297 A novel ultrasound scoring system for giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

Vascular Endothelial Growth Factor as an Aid to Diagnosis of Giant Cell Arteritis
od: Goodfellow, N, i wsp.
Wydane: (2016)

THU0302 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the tabul study (temporal artery biopsy vs ultrasound in diagnosis of giant cell arteritis)
od: Ponte, C, i wsp.
Wydane: (2017)

P1_41 Histology findings in giant cell arteritis (GCA) and their relationship with the ultrasound results: analysis of data from the TABUL study (Temporal Artery Biopsy vs Ultrasound in diagnosis of Giant Cell Arteritis)
od: Ponte, C, i wsp.
Wydane: (2017)

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases
od: Ponte, C, i wsp.
Wydane: (2014)

Optimisation of vasculitis disease assessments in clinical trials, clinical care and long-term databases.
od: Ponte, C, i wsp.
Wydane: (2014)

Is vascular endothelial growth factor a useful biomarker in giant cell arteritis?
od: Goodfellow, N, i wsp.
Wydane: (2017)

Ultrasound for the Diagnosis of Giant Cell Arteritis
od: Paula Valentina Estrada Alarcón, i wsp.
Wydane: (2024-09-01)

Evolution of ultrasound in giant cell arteritis
od: Colm Kirby, i wsp.
Wydane: (2022-10-01)

SY4_1 Giant cell arteritis (GCA) and Takayasu arteritis (TAK): a spectrum within the same disease or not? A report from the DCVAS project
od: Luqmani, R, i wsp.
Wydane: (2017)

Ultrasound Technologies and the Diagnosis of Giant Cell Arteritis
od: Dragoș Cătălin Jianu, i wsp.
Wydane: (2021-11-01)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
od: Ponte, C, i wsp.
Wydane: (2022)

European Headache Federation recommendations for neurologists managing giant cell arteritis
od: S. P. Mollan, i wsp.
Wydane: (2020-03-01)

Treatment of polymyalgia rheumatica and giant cell arteritis: are we any further forward?
od: Luqmani, R
Wydane: (2007)

PREDICTORS OF AORTIC ANEURYSMS FOR GIANT CELL ARTERITIS SUBJECTS
od: Robson, J, i wsp.
Wydane: (2013)

Rho kinase ezpression in giant cell arteritis: validating perm intensity score as a method of increasing sensitivity of temporal artery biopsy
od: Lally, L, i wsp.
Wydane: (2016)

The frequency and severity of patient-reported symptoms in giant cell arteritis
od: Monti, S, i wsp.
Wydane: (2017)

THE FREQUENCY AND SEVERITY OF PATIENT-REPORTED SYMPTOMS IN GIANT CELL ARTERITIS
od: Monti, S, i wsp.
Wydane: (2017)

2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
od: Ponte, C, i wsp.
Wydane: (2022)

Tumor necrosis factor-blocking agents in polymyalgia rheumatica and giant cell arteritis - Reply
od: Luqmani, R
Wydane: (2008)

Updates on the diagnosis and monitoring of giant cell arteritis
od: Sara Monti, i wsp.
Wydane: (2023-02-01)

The association of vascular risk factors with visual loss in giant cell arteritis
od: Yates, M, i wsp.
Wydane: (2016)

Development of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS)
od: Nakagomi, D, i wsp.
Wydane: (2017)

ARE WE MEETING THE STANDARDS FOR TEMPORAL ARTERY BIOPSY IN GIANT CELL ARTERITIS?
od: Soni, A, i wsp.
Wydane: (2009)

The United Kingdom and Ireland Vasculitis Registry: Cross-sectional data on the first 3195 patients with a focus on anti-neutrophil cytoplasm – associated vasculitis and giant cell arteritis
od: Luqmani, R, i wsp.
Wydane: (2017)

The role of ultrasound compared to biopsy of temporal arteries in the diagnosis and treatment of giant cell arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study
od: Luqmani, R, i wsp.
Wydane: (2016)

Giant Cell Arteritis
od: E. V. Shevchenko, i wsp.
Wydane: (2025-01-01)

Giant cell arteritis
od: Dijana Perković, i wsp.
Wydane: (2021-04-01)

Giant Cell Arteritis
od: Bruno Coulier, i wsp.
Wydane: (2018-01-01)

Validity of the EULAR recommendations on the use of ultrasound in the diagnosis of giant cell arteritis
od: Alejandro Balsa, i wsp.
Wydane: (2022-04-01)

O08 Blindness in patients with giant cell arteritis and its association with vascular disease
od: Yates, M, i wsp.
Wydane: (2016)

Giant cell arteritis: new concepts, treatments and the unmet need that remains
od: Coath, F, i wsp.
Wydane: (2018)